Market revenue in 2024 | USD 126.3 million |
Market revenue in 2030 | USD 370.3 million |
Growth rate | 19.6% (CAGR from 2024 to 2030) |
Largest segment | Upstream process |
Fastest growing segment | Downstream Process |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Upstream Process, Downstream Process, Process Development |
Key market players worldwide | Thermo Fisher Scientific Inc, Sartorius AG, Danaher Corp, Merck KGaA, Compagnie de Saint-Gobain SA, Corning Inc, Entegris Inc, Meissner, ProAnalytics, CellBios |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to bioprocess bags market will help companies and investors design strategic landscapes.
Upstream process was the largest segment with a revenue share of 44.42% in 2024. Horizon Databook has segmented the South Korea bioprocess bags market based on upstream process, downstream process, process development covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea is considered a lucrative region to invest in by many global players; the country is witnessing rapid growth in the biomanufacturing space. This has resulted in South Korean firms effectively incorporating bioprocess bags in their bioprocessing operations. Moreover, contract service providers, such as Samsung Biologics, have expanded their businesses in this country.
In April 2022, Samsung Biologics announced full ownership of Samsung Bioepis and a capacity expansion of an existing facility in Incheon, South Korea. Both initiatives were aimed at meeting the growing demand for biologics as well as biosimilar development. Such initiatives are expected to aid in revenue growth in this country during the forecast period.
Moreover, South Korea is witnessing high investments in the growth of its biopharmaceutical industry. For example, in September 2021, Cytiva announced an investment of USD 52.5 million for building a disposable manufacturing facility in South Korea. This expansion was aimed to deliver single-use bags to the bioprocessing industry, which are used in COVID-19 vaccine production.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea bioprocess bags market , including forecasts for subscribers. This country databook contains high-level insights into South Korea bioprocess bags market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account